Paracrine feedback by pancreatic delta cells to control glucagon and insulin release and manage diabetes

Document text

Principal Investigator: Mark O. Huising
Organization: UNIVERSITY OF CALIFORNIA AT DAVIS
Fiscal Year: 2024
Award: $462,960
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases

Half of US adults have diabetes or pre-diabetes, illustrating a critical need for novel treatments. There is a
fundamental gap in the understanding of how paracrine feedback in the islet controls insulin and glucagon. The
long-term goal is to elucidate the (patho)physiological crosstalk within pancreatic islets in order to identify novel
therapeutic targets. The overall objective in this application is to understand how endogenous SST inhibits Ca2+
and cAMP pathways in alpha and beta cells concurrently to balance inhibition of insulin and glucagon exocytosis.
How a single inhibitory hormone can balance the inhibition of beta and alpha cells is a major and poorly
understood aspect of islet physiology. The central hypothesis is that the pancreatic delta cell coordinates with
beta cells to attenuate insulin and glucagon secretion by inhibiting Ca2+ and cAMP while concurrently
remodeling the F-actin cytoskeleton to limit exocytosis. The rationale for the proposed research is that
elucidating the mechanisms and circumstances of delta inhibition of alpha and beta cells would establish a better
understanding of the physiological role of delta cells. This hypothesis will be tested in 3 specific aims. Aim 1 tests
the hypothesis that beta and delta cells coordinate responses largely independently of gap junctions via the
exchange of paracrine factors. Beta and delta cell calcium behavior will be quantified across hundreds of beta
and delta cells in the same intact islets by GCaMP6. Dye injection experiments will determine if gap junctions
can account for the coordinated delta and beta cell behavior. Aim 2 tests the hypothesis that endogenous delta
cell feedback inhibition leads to robust intra-islet elevations of SST that coordinate alpha and beta cell
behaviors via the combined inhibition of cAMP and Ca2+. Beta cells primarily respond to glucose with Ca2+.
Insulin release is potentiated by cAMP. Ca2+ and cAMP will be quantified across hundreds of alpha and beta cells
expressing biosensors for Ca2+ and cAMP in islets with or without SST. We will quantify local SST release via
unique Sstr2 and Sstr3 (ant)agonists to determine the relative importance of cilia SSTR3 and cell-surface Sstr2.
Aim 3 tests the hypothesis that activation of SSTR2 and SSTR3 on alpha and beta cells differentially inhibits
exocytosis by remodeling the cortical F-actin network by activating RhoA GTPase. F-actin remodeling will be
tested directly using FRET biosensors for RhoA expressed by stable MIN6 cells and primary islets in response to
SST, by measuring dynamic remodeling of cortical F-actin via LifeAct, and by quantifying transcriptional changes
to stimulation of primary alpha and beta cells with SSTR2 and SSTR3-selective agonists. The research is
conceptually and technically innovative, in the applicants' opinion, as it evaluates the important physiological
role of delta cells within intact islets in attenuating alpha and beta cell activity. It attains this by applying new
technologies to overcome the hurdles that have previously precluded such studies. This is significant because
delta cell control over glucagon and insulin secretion has broad translational importance towards novel strategies
to curb the diabetes epidemic in the US.

Terms: <21+ years old><3'5'-cyclic ester of AMP><Address><Adenosine Cyclic 3',5'-Monophosphate><Adenosine Cyclic Monophosphate><Adenosine, cyclic 3',5'-(hydrogen phosphate)><Adult><Adult Human><Agonist><Alpha Cell><American><Antidiabetic Hormone><Ants><Attenuated><B9 endocrine pancreas><Behavior><Beta Cell><Biosensor><CDC42><CDC42 gene><CDC42Hs><Calcium><Cell Body><Cell surface><Cells><Cellular Matrix><Cilia><Coloring Agents><Communicating Junction><Congenital Hyperinsulinism><Congenital hyperinsulinemia><Cyclic AMP><Cyclic Somatostatin><Cytoskeletal System><Cytoskeleton><D Cells><D-Glucose><Delta Cell><Dextrose><Diabetes Mellitus><Disease><Disorder><Dyes><Endocrine Gland Secretion><Endocrine Pancreas><Epidemic><Equilibrium><Exocytosis><Exocytosis Inhibition><F-Actin><FRET><Feedback><Filamentous Actin><Fluorescence Resonance Energy Transfer><Förster Resonance Energy Transfer><G25K><GTP Phosphohydrolases><GTPases><Gap Junctions><Gene Transcription><Genetic Transcription><Glucagon><Glucagon Cell><Glucagon Secreting Cell><Glucose><Glukagon><Goals><Growth Hormone Inhibiting Factors><Growth Hormone-Inhibiting Hormone><Guanosine Triphosphate Phosphohydrolases><Guanosinetriphosphatases><HG-Factor><Health><Hormones><Humulin R><Hyperglycemia><Hyperglycemic-Glycogenolytic Factor><Hyperinsulinemia Hypoglycemia of Infancy><Hypoglycemia><Hypoglycemia of Infancy><Individual><Injections><Insulin><Insulin Cell><Insulin Secreting Cell><Insulin deficiency><Islands of Langerhans><Islet Cell><Islets of Langerhans><Learning><Literature><Liver><Low-resistance Junction><Measures><Mediating><Mission><NIDDK><National Institute of Diabetes and Digestive and Kidney Diseases><Nesidioblasts><Nexus Junction><Novolin R><Nutrient><PHHI Hypoglycemia><Pancreatic Islets><Pancreatic Somatostatin Cell><Pancreatic Somatostatin Secreting Cell><Pancreatic beta Cell><Pancreatic delta Cell><Pancreatic β-Cell><Pancreatic δ Cell><Pars endocrina pancreatis><Pathway interactions><Patients><Persistent Hyperinsulinemia Hypoglycemia of Infancy><Physiologic><Physiological><Physiology><Position><Positioning Attribute><Prediabetes><Prediabetes syndrome><Prediabetic State><Public Health><Publishing><QOL><Quality of life><RNA Expression><Regular Insulin><Research><Role><SRIH><SRIH Receptors><SRIH-14><SSTR2><SSTR2 gene><SSTR3><SSTR3 gene><Somatostatin><Somatostatin Cell of the Pancreas><Somatostatin Cells><Somatostatin Receptor><Somatostatin Secreting Cell><Somatostatin Secreting Cell of the Pancreas><Somatostatin-14><Somatotropin Release Inhibiting Factors><Somatotropin Release Inhibiting Hormone Receptors><Somatotropin Release-Inhibiting Hormone><Source><Structure of beta Cell of islet><Testing><Therapeutic><Therapeutic Hormone><Time><Tolbutamide><Transcription><Translating><adenosine 3'5' monophosphate><adulthood><alpha-cell><attenuate><attenuates><balance><balance function><biological sensor><blood glucose regulation><cAMP><cell behavior><cellular behavior><diabetes><diabetes management><diabetes mellitus management><diabetic management><experiment><experimental research><experimental study><experiments><glucose control><glucose homeostasis><glucose regulation><growth hormone release inhibiting factor><guanosinetriphosphatase><hepatic body system><hepatic organ system><hyperglycemic><hypoglycemic><hypoglycemic episodes><improved><innovate><innovation><innovative><insulin secretion><intracellular skeleton><islet><islet progenitor><new approaches><new drug target><new druggable target><new pharmacotherapy target><new technology><new therapeutic target><new therapy target><novel><novel approaches><novel drug target><novel druggable target><novel pharmacotherapy target><novel strategies><novel strategy><novel technologies><novel therapeutic target><novel therapy target><pancreas beta cell><pancreas delta cell><pancreas β cell><pancreatic b-cell><paracrine><pathway><pre-diabetes><pre-diabetic><prediabetic><prevent><preventing><response><restraint><social role><standard care><standard treatment><type 1 and type 2 diabetes><type I and type II diabetes><α-cell><β-cell><β-cells><βCell>